GLPwatch
Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials.
Expert Opin Pharmacother · 2011
Last updated 2026-05-28A review of clinical trials found that both sitagliptin and exenatide once weekly can lower blood sugar control (HbA1c) and plasma glucose levels in people with type 2 diabetes. However, exenatide once weekly was more effective than sitagliptin in these trials.
AI summary of the abstract below.
| Journal | Expert Opin Pharmacother, 2011 |
|---|---|
| Citations | 1 |
| Relative citation ratio | 0.04 |
| NIH percentile | 4 |
| Molecules | exenatide |
| Conditions studied | Type 2 Diabetes |
Abstract
INTRODUCTION: There is a need for new and improved treatments for type 2 diabetes. Glucagon-like peptide 1 (GLP-1) is a gut hormone that stimulates insulin secretion and the levels of GLP-1 can be increased by inhibiting DPP-4. Sitagliptin is one of the DDP-4 inhibitors used to increase the levels of GLP-1. Exenatide is an agonist at the GLP-1 receptors, which is resistant to breakdown and has a longer action than GLP-1.
AREAS COVERED: This review compares the clinical trials of sitagliptin and exenatide once weekly in the treatment of type 2 diabetes. Only peer-reviewed trials listed on PubMed were included.
EXPERT OPINION: Both sitagliptin and exenatide once weekly are capable of reducing HbA1c and plasma glucose levels, but exenatide once weekly is more potent than sitagliptin and this may lead to different roles for these agents in the treatment of type 2 diabetes.
Verbatim abstract via PubMed 21534885 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.